Effect of Sofosbuvir on Length of Hospital Stay in Moderate COVID-19 Cases; a Randomized Controlled Trial

• Published in: Archives of academic emergency medicine 2022-01, Vol.10 (1), p.e46-e46
• Main Authors: Bozorgmehr, Rama, Amiri, Farbod, Hosein Zadeh, Mohammad, Ghorbani, Fariba, Khameneh Bagheri, Arash, Yazdi, Esmat, Nekooghadam, Sayyed Mojtaba, Pourdowlat, Guitti, Fatemi, Alireza
• Format: Article
• Language: English
• Subjects: Duration of Therapy; Original; SARS-CoV-2; Sofosbuvir; Treatment Outcome
• ISSN: 2645-4904
• DOI: 10.22037/aaem.v10i1.1621

IntroductionEfforts to control the COVID-19 pandemic are still on. This study aimed to evaluate the effect of sofosbuvir on length of hospital stay and complications in COVID-19 cases with moderate severity. MethodsThis randomized clinical trial was done on moderate COVID-19 cases, who were admitted to Shohadaye Tajrish Hospital, Tehran, Iran, from 4/2021 to 9/2021. Eligible patients were randomly allocated into two groups of intervention (sofosbuvir) and control, and their outcomes were compared regarding the length of hospital stay and complications. Results100 COVID-19 cases were randomly divided into two groups of 50 patients, as the intervention and control groups. The mean age of patients was 50.56 ± 12.23 and 57.1±14.1 years in the intervention and control groups, respectively (p = 0.02). The two groups were similar regarding distribution of gender (p = 0.15), underlying diseases (p = 0.08), the severity of COVID-19 (p = 0.80) at the time of admission, signs and symptoms (p > 0.05), and essential laboratory profile (p > 0.05). The length of hospital stay in the control and intervention groups was 7.7 ± 4.09 days and 4.7±1.6 days, respectively (p = 0.02). None of our patients needed ICU or mechanical ventilation. ConclusionSofosbuvir may decrease the length of hospital stay of COVID-19 cases with moderate severity, without a significant effect on the rate of intensive care unit (ICU) need and mortality.